arrow
G

Gustavo E. Velásquez

university of california san francisco
H指数:16
被引数:958

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

2026-08-140
PRE
Pharmacokinetic and pharmacogenomic predictors of hepatotoxicity in the HIRIF trial for drug-susceptible tuberculosis

药物敏感结核病患者HIRIF试验中肝毒性的药代动力学和药物基因组学预测因子

2026-03-060
OA
Tuberculosis Infection Screening Recommendations for Targeted Immunotherapies: Comparison of US Prescribing Information, Clinical Resources, and Quality Measures

结核感染筛查建议:针对免疫疗法的目标人群——美国处方信息、临床资源和质量指标的对比

2026-01-010
PRE
Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial

贝达喹啉、德拉马尼、利奈唑胺和氯法齐明用于利福平耐药和氟喹诺酮类耐药结核病(endTB-Q):一项开放标签、多中心、分层、非劣效性、随机对照、III期试验

2025-07-160
PREAI
Impact of Pharmacogenetics on Pharmacokinetics of First-Line Antituberculosis Drugs in the HIRIF Trial

HIRIF试验中药物基因组学对一线抗结核药物药代动力学的影响

2025-04-170
PRE
Risk-stratified treatment for drug-susceptible pulmonary tuberculosis

药物敏感肺结核的风险分层治疗

2024-10-301
OA
Recent advances in the treatment of tuberculosis

结核病治疗的最新进展

2024-09-0113
OA
Pharmacokinetic-Pharmacodynamic Evidence From a Phase 3 Trial to Support Flat-Dosing of Rifampicin for Tuberculosis
2024-03-110
OAAI
Standards for clinical trials for treating TB
2023-12-013
OAAI
Scientific advances and the end of tuberculosis: a report from the Lancet Commission on Tuberculosis
LANCET
IF88.5
2023-10-0114
PRE
Respiratory, Cardiac, and Neuropsychiatric Manifestations of Postacute Sequelae of Coronavirus Disease 2019 in Lima, Peru
2023-06-200
OAAI